Indian Journal of Palliative Care
Open access journal 
  Print this page Email this page   Small font sizeDefault font sizeIncrease font size Users online: 388  
     Home | About | Feedback | Login 
  Current Issue Back Issues Editorial Board Authors and Reviewers How to Subscribe Advertise with us Contact Us Analgesic Prescription  
  Navigate Here 
 »   Next article
 »   Previous article
 »   Table of Contents

 Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded4    
    Comments [Add]    

Recommend this journal


Year : 2021  |  Volume : 27  |  Issue : 1  |  Page : 43--46

Prediction of survival outcome using Chuang's prognostic scale in metastatic breast cancer

1 Department of Medical Oncology, Faculty of Medicine, Zagazig University, Zagazig, Egypt; Oncology Center, King Salman Armed Forces Hospital, Tabuk, KSA
2 Oncology Center, King Salman Armed Forces Hospital, Tabuk, KSA
3 Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Suez Canal University, Cairo, Egypt
4 Kasr EL Einy Center of Clinical Oncology and Nuclear Medicine (NEMROCK), Cairo University, Cairo, Egypt

Correspondence Address:
Amrallah A Mohammed
29 Saad Zaghloul, Postal Code 44519

Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/IJPC.IJPC_97_20

Rights and Permissions

Background: For physicians and patients, survival estimation is vital for the treatment plan, especially with frequent use of new therapeutic agents in metastatic breast cancer (MBC). The Chuang's Prognostic Scale (CPS) is a validated prognostic score that may be useful in the avoidance of unnecessary palliative systemic treatment. Aim: The present study aimed to evaluate the CPS in survival prediction in patients with MBC after at least two lines of palliative systemic chemotherapy protocols (PSCPs). Methods: CPS was prospectively measured in 221 patients with MBC. The total score ranged from 0 to 8.5; the lower score refers to a good prognosis. The survival assessment was made by the Kaplan–Meier curve and the survival difference among the groups was estimated by log-rank test. Results: Using the cutoff value of CPS 5.7, the patients were classified into two groups: Group A had score ≤5.7 (174 patients, 78.7%) and Group B had CPS score >5.7 (47 patients, 21.3%). About 86.2% of the patients in Group A survived >3 months (median survival was 165 days, 95% confidence interval [CI]: 77–261) compared with 21.3% of patients survived in Group B (median survival was 81 days, 95% CI: 55–123) (P = 0.00). The sensitivity, specificity, positive predictive value, and negative predictive value were 97.6% (95% CI: 87.4–99.9), 98.3% (95% CI: 95.2–99.7), 93.2% (95% CI: 81.6–97.7), and 99.4% (95% CI: 96.2–99.9), respectively, for the 3-month mortality prediction. Conclusion: CPS could be helpful in estimating the survival outcome in patients with MBC who received at least two PSCPs.


Print this article     Email this article

Online since 1st October '05
Published by Wolters Kluwer - Medknow